Al Maqbali M, Al Sinani M, Al Naamani Z, et al. - To determine fatigue prevalence in cancer patients, researchers explored PubMed, MEDLINE, EMBASE, PsycINFO, Cochrane Library, from inception up to February 2020. As a result, they identified 129 studies ( N = 71,568) published between 1993 and 2020. These studies satisfied the inclusion criteria. For fatigue, an overall prevalence of 49% was reported, with significant heterogeneity between studies. In subgroup analyses, it was revealed that prevalence of fatigue associated with type of cancer ranged from 26.2% in patients suffering from gynecological cancer to 56.3% in studies that involved mixed types of cancer. There was the highest prevalence of fatigue (60.6%) in patients with advanced cancer stage. During treatment and during mixed treatment status, the prevalence rates for fatigue were estimated to be 62% and 51%, respectively. A significant moderator for higher prevalence of fatigue was female gender, as shown on metaregression. Overall, the importance of creating optimal monitoring strategies to attenuate fatigue and enhance the quality of life of cancer patients was highlighted by the findings of this meta-analysis.